In T2DM patients, the SGLT2-i have been shown to improve cardiac function (17), reduce hospitalizations, and positively impact prognosis in patients with stable ischemic heart disease undergoing surgical revascularization (18). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.